Canaccord raised the firm’s price target on Thorne HealthTech to $7 from $6 and keeps a Buy rating on the shares. The firm said they had a top and bottom line beat and were able to see improved gross margins and strong operating leverage in the quarter due to sales coming ahead of expectations along with efficient marketing spend. Canaccord believes the company is positioned well for the future as demand still outweighs production capabilities, leading management to invest in their manufacturing capabilities to be able to meet projected demand through 2030.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on THRN:
- Thorne HealthTech raises FY23 adjusted EPS view to 26c-32c from 25c-31c
- Thorne HealthTech reports Q2 adjusted EPS 15c, consensus 6c
- Thorne HealthTech Reports Second Quarter 2023 Results
- Thorne HealthTech working with bank to explore sale, Reuters reports
- Thorne jumps 12% to $5.88 after Reuters report of exploring sale